Quantification and application of the placental epigenetic signature of the RASSF1A gene in maternal plasma

Academic Article

Abstract

  • Objectives: The aims of the detection of hypermethylated RASSF1A gene in maternal plasma from all three trimesters of pregnancy were to show its feature of cell-free fetal DNA and to make up deficients of genetic markers. This study also aimed at investigating of its application value in pre-eclampsia compared with third trimester. Methods: Eighty pregnant women (7-41 gestational weeks) including normal pregnant women (60 cases) and pre-eclamptic pregnant women (20 cases) were selected as study groups and 20 normal non-pregnant women were selected as control group. Free DNA of plasma samples was extracted, and RASSF1A levels before and after double-methylation-sensitive restriction enzyme digestion of HinP1I and HhaI were determined to measure total and fetal cell-free DNA, respectively. β-Actin gene was detected as a control to confirm complete enzyme digestion. Results: The median concentrations of hypermethylated RASSF1A gene were 46 copies/mL in first trimester, 96 copies/mL in second trimester, 527 copies/mL in third trimester and 1947 copies/mL in pre-eclampsia. There was positive correlation between fetal-derived hypermethylated RASSF1A levels and the severity of pre-eclampsia. Conclusion: Hypermethylated RASSF1A gene may be considered as an epigenetic marker to detect the fetal DNA in maternal plasma and expands the clinical application of non-invasive prenatal diagnosis. Copyright © 2010 John Wiley & Sons, Ltd.
  • Published In

  • Prenatal Diagnosis  Journal
  • Digital Object Identifier (doi)

    Author List

  • Zhao F; Wang J; Liu R; Yang J; Cui K; Wu Y; Guo J; Mu Y; Wang X
  • Start Page

  • 778
  • End Page

  • 782
  • Volume

  • 30
  • Issue

  • 8